These experimental observations were confirmed in colorectal cancer patients, in whom a higher prevalence of unfavorable chemotherapeutic response was noted in subjects with cNrf2- and PSMD4-positive tumors [155]. The gene discussed is PSMD4; the disease is colorectal cancer.